RxNorm 2534241
tivozanib Oral Capsule [Fotivda]
RxNorm Semantic Concepts
RxNorm semantic concepts for the RxCUI 2534241 unique identifier include: tivozanib Oral Capsule [Fotivda] (12620233).
RxNorm Atom ID: 12620233 - Semantic Branded Drug Form
tivozanib Oral Capsule [Fotivda]
- RXCUI:
- 2534241 - RxNorm Unique Identifier for a concept (Concept ID)
- LAT:
- ENG - Language of the Term
- RXAUI:
- 12620233 - Unique identifier for the atom (RxNorm Atom ID)
- Is Prescribable?
- YES - This drug is part of the RxNorm Current Prescribable Content, a subset of RxNorm that includes all drugs available for prescription in the United States. The Current Prescribable subset also includes over-the-counter drugs.
- Concept Description:
- tivozanib Oral Capsule [Fotivda] - Description of concept identifier
- Term Type (TTY):
- SBDF - Term type in source with name and description
- Term Type Name:
- Semantic Branded Drug Form - Name of term type in source
- Term Type Description:
- Ingredient + Dose Form + Brand Name - Description of term type in source
- Code:
- 2534241 - "Most useful" source asserted identifier. If the source vocabulary has more than one identifier, or a RxNorm-generated source entry identifier. (if the source vocabulary has none.)
- Suppress Flag:
- N
Suppressible flag. Values = N, O, Y, or E. N - not suppressible. O - Specific individual names (atoms) set as Obsolete because the name is no longer provided by the original source. Y - Suppressed by RxNorm editor. E - unquantified, non-prescribable drug with related quantified, prescribable drugs. NLM strongly recommends that users not alter editor-assigned suppressibility. - CVF:
- 4096 - Content view flag. RxNorm includes one value, '4096', to denote inclusion in the Current Prescribable Content subset. All rows with CVF='4096' can be found in the subset.
- Source:
- RXNORM - Concept source abbreviation
- Source Name:
- RxNorm Vocabulary - The official name for a source
- Source Version:
- 20AA_240603F - The source version
- Source Date:
- June 03, 2024 - RxNorm data last updated
- Source License Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source license contact information - Source Content Contact:
- RxNorm Customer Service
U.S. National Library of Medicine
8600 Rockville Pike
Bethesda
MD
United States
20894
(888) FIND-NLM
[email protected]
https://www.nlm.nih.gov/research/umls/rxnorm/ - The source content contact information - Source Short Name:
- RxNorm work done by the National Library of Medicine - The short name of a source as used by the NLM Knowledge Source Server
* This product uses publicly available data courtesy of the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Patient Education
Tivozanib
Tivozanib is used to treat advanced renal cell carcinoma (RCC; cancer that begins in the kidneys) that has returned or did not respond to at least two other medications. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
[Learn More]
* Please review the disclaimer below.